NOIDA, India and NEW HOPE, Pa., Jan. 13 /PRNewswire/ -- Jubilant Organosys Ltd., headquartered at Noida, near New Delhi, announced today that its Bangalore-based subsidiary, Jubilant Biosys Ltd., has entered into a drug discovery partnership with BioLeap, LLC, USA. Under this partnership, BioLeap and Jubilant will integrate BioLeap's leading edge computational fragment based drug design platform with Jubilant's expertise in chemistry, biology and crystallography to offer a highly competitive preclinical drug development platform. The partnership will provide customers with integrated pre-clinical drug discovery services from lead identification and optimization to IND (Investigational New Drug) candidate selection for multiple therapeutic areas.
Commenting on the development, Sri Mosur, CEO & President, Jubilant Biosys, said: "We are very pleased to partner with BioLeap to offer the pharmaceutical industry our combined 'best in class' preclinical drug discovery capabilities."
Gerald Evans, BioLeap Chief Business Officer added, "We are delighted to have the opportunity to offer our partners the combined capabilities of Jubilant and BioLeap. This partnership leverages and combines the innovation capabilities of Jubilant Biosys in pharmaceutical discovery and preclinical development with BioLeap's leading edge computational fragment-based design capabilities, to deliver high quality, cost-effective pre-clinical drug discovery services."
BioLeap's platform technology is completely "in-silico," and it quickly predicts binding information providing drug designers new insights to efficiently create novel molecules and/or improve existing molecules without the limitations of library screening, thereby reducing the time and cost of traditional screening methods.
Many current screening programs have hit barriers with regards to finding small molecule candidates for viable validated targets because of limitations in chemical diversity. BioLeap's technology provides a viable solution to this current paradigm. The combined strengths of JBL/BioLeap partnership would be most attractive to companies engaged in rational drug design in therapeutic areas where Structural Biology plays a key role, which includes but is not limited to any of the top twenty pharmaceutical companies working on anti-infectives, oncology, CNS and other therapeutic areas.
About Jubilant Biosys
Jubilant Biosys Ltd. (http://www.jubilantbiosys.com) is a subsidiary of Jubilant Organosys Ltd., which provides integrated drug discovery and development solutions to the global pharmaceutical industry. The 120,000 sq. ft. state of the art Jubilant Biosys Center in Bangalore integrates the capabilities of over 300 scientists specializing in multiple disciplines including biology, chemistry, structural biology, pharmacology, molecular modeling, crystallography and information technology to support collaborations with global pharma companies in USA, Europe and Japan.
About Jubilant Organosys
Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The company has a presence across the pharmaceutical value chain for products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and Health Care. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these help Jubilant cater to 150 customers across more than 50 countries around the world.
About BioLeap
BioLeap is a leader in computational fragment-based drug design. The company's proprietary design technology and process successfully addresses one of the biggest problems in pre-clinical drug discovery: the limitation of druggable and patentable leads for important biological targets. BioLeap is using its capabilities to advance its internal programs and has also entered into numerous drug design collaborations with pharmaceutical partners.
Further information about Jubilant Organosys is available at http://www.jubl.com and about BioLeap at http://www.bioleap.com.
CONTACT: India, Media, Seema Ahuja, VP - Corporate Marketing &
Communications, +91-120-4361062, Mobile, +91-9810631779,
seema_ahuja@jubl.com, or Investors, Deepak Malik, Manager - Investor
Relations, +91-120 4361114, Fax, +91-120- 2516629, deepak_malik@jubl.com,
both of Jubilant Organosys Limited; or Satyam Chauhan of Imprimis Life PR,
+91 9711677607, schauhan@imprimispr.com; or Siddharth Rangnekar of Citigate
Dewe Rogerson, +91 -22 4007 5005, Fax, +91-22- 2284 4561,
siddharth@cdr-india.com; or Business Queries, USA, Corey Jacklin, Director,
Business Development of Jubilant Biosys, +1-215-369-0965,
Corey_Jacklin@jubilantbiosys.com; or Gerald H. Evans, EVP and Chief
Business Officer of BioLeap, +1-215-371-2874, GHE@bioleap.com
Web site: http://www.jubilantbiosys.com/
http://www.jubl.com/
http://www.bioleap.com/
